Article Information
History
- February 14, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Natalia Mitin, PhD1,
- Kirsten A. Nyrop, PhD2,3,
- Susan L. Strum, MS1,
- Anne Knecht, PhD1,
- Lisa A Carey, MD2,3,
- Katherine E. Reeder-Hayes, MD2,3,
- E. Claire Dees, MD2,3,
- Trevor A. Jolly, MBBS2,3,
- Gretchen G. Kimmick, MD4,
- Meghan S. Karuturi, MD5,
- Raquel E. Reinbolt, MD6,
- JoEllen C. Speca, MD2,3,
- Erin A. O’Hare, RD, MA2,3 and
- Hyman B. Muss, MD2,3,*
- 1Sapere Bio, Research Triangle Park, NC
- 2School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 3Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 4Duke University School of Medicine, Durham NC
- 5MD Anderson Cancer Center, University of Texas, Houston TX
- 6Ohio State University Comprehensive Cancer Center, Columbus OH
- ↵*Corresponding author: Hyman B. Muss, MD, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; hyman_muss{at}med.unc.edu
Posted February 14, 2022.
A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer
